ASH is just over a month away. Come meet with the GTC team and its co-op partners at our happy hour event.
Download your invitation Here

Background VEXAS syndrome is a disease with inflammatory and hematologic (blood) manifestations. The syndrome is caused by mutations in the UBA1 gene affecting the Met41 residue of the protein and resulting in
A Man with a Recurrent Left Pleural Effusion In late 2020, a new disease entity that was referred to as VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome was reported.
GTC scientists collaborate with the NIH on a study just published in the Journal of Clinical Oncology. The publication is titled: Prediction of outcome in CLL patients treated with ibrutinib:
Get all the critical news and events sent straight to your inbox